絞り込み

16514

広告

Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.

著者 Ozaki H , Harada S , Takeuchi T , Kawaguchi S , Takahashi Y , Kojima Y , Ota K , Hongo Y , Ashida K , Sakaguchi M , Tokioka S , Sakamoto H , Furuta T , Tominaga K , Higuchi K
Digestion.2018 Jan 31 ; 97(3):212-218.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (210view , 0users)

Full Text Sources

Phase III study demonstrated that vonoprazan-based Helicobacter pylori eradication therapy achieved higher eradication rate compared with lansoprazole. However, there is no study that evaluated the efficacy of vonoprazan in a large sample in real world. We investigated the eradication rate and safety of vonoprazan-based eradication therapy compared with our randomized control trial using second-generation proton pump inhibitor (PPIs).
PMID: 29393194 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード